<DOC>
	<DOC>NCT00885547</DOC>
	<brief_summary>The purpose of this study is to: 1. To evaluate the latest effects of TW for IgA nephropathy (IgAN) with asymptomatic abnormal urinalysis. 2. To evaluate the safety and tolerability of TW.</brief_summary>
	<brief_title>Prospective Study of TW in Treatment of IgAN With Asymptomatic Abnormal Urinalysis</brief_title>
	<detailed_description>Patients who fit the inclusion criteria will be randomly divided into three groups: TW group (TW at dosage of 90 mg/d), ARB group (the control group, valsartan at dosage of 160 mg/d) and combined treatment group (TW at dosage of 60 mg/d and valsartan at dosage of 80 mg/d).</detailed_description>
	<mesh_term>Glomerulonephritis, IGA</mesh_term>
	<criteria>1. 1860 years old but no requirement for gender 2. All well fit the Diagnostic Criteria for Primary IgAN and IgAN with asymptomatic abnormal urinalysis 3. Informed consent is obtained from each research subject who agrees to conduct a periodic followup according to the research arrangement 1. Secondary IgA nephropathy, such as HenochSch√∂nlein purpura nephritis, Lupus nephritis and so on 2. Some secondary kidney diseases like diabetic nephropathy or other systemic diseases which may effect the pathologic and physiological function of kidney like hypertension and arteriosclerosis 3. Severe infection 4. Abnormality of liver function with glutamic pyruvic transaminase (GPT) or glutamicoxal(o)acetic transaminase (GOT) more than twice upper limit of normal 5. Women during pregnancy and lactation 6. Patients need to procreation lately 7. Patients treated with TW or ARB within 4 months</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>